Thank you.
If you can't fully answer, then perhaps you could submit....
Building on Mr. Fletcher's point, I'm pleased about the progressive licensing, where we can get out breakthrough drugs as quickly as possible to benefit...and then we continue. But this brings about the problem of off-label use, which could be of great benefit to patients and to the medical community. Because of its use, it doesn't lend itself to adverse event reporting.
I hope you can find a way to marry the two proposals, permitting off-label use and doing the progressive licensing so they can be brought in.